Loading company…
Novorex develops small-molecule drugs for oncology and neurological diseases.
Founded in 2020 in South Korea, Novorex uses protein structures and molecular calculations to develop drugs for oncology and neurology. Its systems include Seamless Drug Discovery, Deep Designer and Novo Picker. In April 2026, the company raised KRW 21 billion in Series B funding to support global Phase 1 trials of NRX-NGT002, a Parkinson's disease treatment targeting LRRK2.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in